The tumor microenvironment is a complex and dynamic ecosystem, where cancer cells coexist with diverse populations of immune and stromal cells, each influencing — and sometimes hijacking — one another’s functions. While the focus for years has been on understanding how tumor cells proliferate, an increasing body of evidence highlights the critical influence of non-cancerous cells in dictating tumor fate. Neutrophils, the most abundant white blood cells and principal responders in acute infection, have emerged as enigmatic players in this intricate milieu, often associated with poor patient prognosis in solid cancers.

This latest study spearheaded by Mikaël Pittet, professor and expert in pathology and immunology at UNIGE, and his team, revealed that neutrophils infiltrating tumors undergo a functional transformation that subverts their canonical anti-microbial roles. When exposed to the tumor ecosystem, these neutrophils begin producing elevated levels of CCL3, a chemokine traditionally implicated in leukocyte recruitment and inflammation, which paradoxically promotes tumor progression rather than inhibiting it.

Neutrophils are notoriously challenging to study given their short lifespan and delicate nature, compounded by technical hurdles in manipulating their gene expression. Evangelia Bolli, co-lead author responsible for the experimental work, described the sophisticated genetic approaches developed to selectively modulate CCL3 expression in neutrophils, without affecting other cells. This precise targeting revealed the indispensable role of neutrophil-derived CCL3 in fostering a pro-tumor microenvironment. Strikingly, neutrophils devoid of CCL3 retained their circulatory functions and were still recruited to tumors but failed to facilitate tumor growth, marking this chemokine as a critical switch in their deleterious reprogramming.

Complementing the experimental data, bioinformatics expertise by Pratyaksha Wirapati forged innovative analysis tools to identify neutrophils more reliably across broad cancer datasets. Due to their inherently low transcriptional activity, neutrophils had long evaded detection in conventional genomic analyses. This breakthrough methodology enabled the detection of a consistent pattern: across multiple cancers, aged neutrophils become CCL3-overexpressing agents closely linked with aggressive tumor phenotypes, underscoring the universality of this mechanism.

The implications for clinical oncology are profound. Historically, biomarkers capable of accurately predicting tumor progression have been limited and often insufficiently precise. The team’s parallel earlier work involving two macrophage genes correlated with clinical outcomes highlighted the multifactorial nature of tumor evolution. Adding neutrophil-derived CCL3 as a second key variable refines the emerging concept of a ‘tumor identity card’—a composite molecular signature that encapsulates the tumor’s intrinsic biology and trajectory.

Armed with this knowledge, future diagnostic approaches could leverage neutrophil CCL3 expression as a prognostic indicator, guiding therapeutic decisions and potentially enabling timely interventions tailored to a patient’s tumor ecosystem. Moreover, therapeutics that target neutrophil reprogramming or specifically inhibit CCL3 signaling pathways might unlock novel avenues for cancer treatment, transforming immune cells from facilitators of malignancy back to allies in immune surveillance.

This research also emphasizes the dual-edged nature of immune responses in cancer biology. While neutrophils conventionally provide frontline defense against pathogens, their plasticity within the tumor microenvironment allows malignant cells to co-opt these cells, turning an erstwhile protector into a promoter of disease. Understanding these contextual functional switches is critical for designing immunotherapies that can effectively recalibrate the immune landscape towards tumor eradication.

The study’s interdisciplinary approach—marrying experimental genetics, in vivo tumor models, and advanced computational methods—epitomizes the modern scientific modus operandi necessary to decode cancer’s complexity. Each layer of analysis reinforces the conclusion: neutrophil-mediated secretion of CCL3 is a determinant factor in tumor pathogenesis, representing both a biological insight and a therapeutic vulnerability.

Looking ahead, deciphering how neutrophils transition into this CCL3-producing state and identifying the molecular cues from the tumor microenvironment that drive this process remain imperative next steps. Such knowledge could reveal upstream regulators amenable to pharmacological inhibition, further expanding the arsenal against tumor progression.

In sum, these findings herald a paradigm shift in oncology, spotlighting the nuanced roles immune cells play beyond simplistic anti- or pro-tumor categorizations. As research continues to peel back the layers of tumor ecology, variables like neutrophil-derived CCL3 will be instrumental in building predictive models that translate into real-world patient benefits, ultimately advancing the era of personalized cancer medicine.

Subject of Research: Immune cell reprogramming in cancer; neutrophil function and chemokine CCL3 in tumor progression

Article Title: “CCL3 is produced by aged neutrophils across cancers and promotes tumor growth”

News Publication Date: 5-Feb-2026

Web References:

• DOI: 10.1016/j.ccell.2026.01.006
• University of Geneva media release on related gene expression study: https://www.unige.ch/medias/en/2023/une-paire-de-genes-pourrait-predire-levolution-du-cancer

Image Credits: © Mikaël Pittet – UNIGE

Keywords: tumor microenvironment, neutrophils, CCL3 chemokine, immune reprogramming, cancer progression, bioinformatics, immune biomarkers, personalized oncology, tumor ecology

The phenomenon at the center of this discovery is clonal haematopoiesis of indeterminate potential (CHIP). CHIP emerges when hematopoietic stem cells in the bone marrow acquire somatic mutations as individuals age and are exposed to environmental stresses. Although CHIP has been previously associated with increased risks for cardiovascular diseases and blood cancers, its role in the evolution of solid tumors remained unclear until now. By leveraging large-scale genomic and clinical data sets, the researchers were able to establish that CHIP mutations are present in the circulating blood of cancer patients and critically, in a substantial proportion of tumor-infiltrating immune cells.

This comprehensive study incorporated data from over 400 lung cancer patients enrolled in the Cancer Research UK-funded TRACERx and PEACE trials, as well as an expansive cohort of nearly 49,000 patients with various cancer types treated at Memorial Sloan Kettering Cancer Center. Blood samples from these cohorts underwent deep sequencing to identify the presence of CHIP mutations. Matching the genomic data with clinical outcomes uncovered a stark correlation: patients harboring CHIP mutations exhibited markedly reduced overall survival, independent of their age or tumor stage at diagnosis. This observation introduced a previously unappreciated dimension of how age-related clonal blood mutations can influence cancer prognosis.

Digging deeper, the team identified a subset of patients in whom these mutated blood cells had physically infiltrated the tumor microenvironment, a situation they termed tumor-infiltrating clonal haematopoiesis (TI-CH). Remarkably, about 42% of patients with CHIP demonstrated TI-CH, highlighting the significant cross-talk between the hematopoietic system and tumor biology. It was TI-CH, rather than CHIP alone, that emerged as a powerful predictor of cancer relapse and mortality, thus emphasizing the biological relevance of these infiltrating mutant cells.

Further investigation into metastatic sites, studied through postmortem analyses under the PEACE protocol, reinforced the notion that TI-CH is not confined to primary tumors but is prevalent in secondary lesions where cancer dissemination occurs. The presence of TI-CH mutations in metastatic foci implicates these mutant myeloid cells as active players in the terminal phases of cancer progression, possibly facilitating the establishment and persistence of aggressive disease phenotypes.

Crucially, the study dissected the cellular composition and genotypic profiles of these tumor-infiltrating cells. Myeloid cells—a diverse group of immune cells involved in inflammation and tissue remodeling—were found to be the predominant cell type housing CHIP mutations within the tumor microenvironment. Unlike cytotoxic lymphocytes that target and eliminate cancer cells, myeloid cells often adopt immunosuppressive or tumor-supportive roles. This shift in immune landscape could enable tumor cells to evade immune surveillance and accelerate their growth and spread.

Among the mutated genes identified within TI-CH cells, TET2 stood out due to its critical regulatory functions in hematopoiesis and epigenetic control. TET2 mutations were disproportionately represented in tumor-infiltrating myeloid populations compared to other immune subsets. By analyzing hundreds of single cells from tumors of patients with TI-CH, the researchers confirmed that these alterations were predominantly restricted to myeloid cells, indicating a selective advantage or tropism for TET2 mutant cells to colonize the tumor microenvironment.

To translate these observations into functional insights, the research team collaborated with experts on blood cancers and CHIP at the Crick Institute, including the laboratory led by Dominique Bonnet. Together, they engineered three-dimensional lung tumor organoids co-cultured with TET2 mutant myeloid cells, effectively mimicking the complex interactions within human tumors. The presence of mutant myeloid cells induced pronounced remodeling of the tumor microenvironment and accelerated organoid growth, providing experimental evidence that TET2 mutations in infiltrating immune cells actively foster tumor progression rather than serving as passive bystanders.

Expanding the scope of their findings, the investigators examined a diverse array of cancers beyond lung cancer, validating TI-CH as an independent prognostic factor for reduced survival across multiple tumor types. Notably, TI-CH prevalence was elevated in malignancies historically linked with poor therapeutic responses, including pancreatic cancer and head and neck squamous cell carcinomas. This suggests that age-related clonal hematopoiesis may contribute to the treatment resistance observed in these cancer subsets, potentially through modulation of the tumor immune milieu.

This research marks a pivotal milestone in clarifying the interface between aging, clonal hematopoiesis, and cancer biology. While prior studies have focused on intrinsic tumor mutations and microenvironmental factors, the recognition that mutated blood-derived immune cells infiltrate and reprogram tumors introduces a paradigm shift. Understanding the precise molecular mechanisms by which CHIP-driven TI-CH influences cancer cell behavior and immune evasion could unlock new avenues for targeted therapies and intervention strategies.

Future research directions, as outlined by the team, will focus on establishing the causal relationships linking CHIP and aggressive cancer phenotypes, alongside elucidating the signaling pathways governing myeloid cell expansion and tumor infiltration. Such knowledge may pave the way for novel clinical approaches to modulate the impact of clonal hematopoiesis—either by targeting mutant myeloid populations or by reversing their tumor-promoting activities.

Oriol Pich, a postdoctoral scientist at the Crick’s Cancer Evolution and Genome Instability Laboratory and lead author of the study, stressed the clinical significance of these findings: “Our results reveal that blood cells carrying age-related mutations are not mere passive passengers but can actively infiltrate tumors, shaping cancer evolution and ultimately influencing patient outcomes.” The study highlights CHIP as a widespread, age-associated phenomenon common in cancer patients, underscoring the need to consider patient age and hematopoietic mutation status in personalized oncology.

Charlie Swanton, Deputy Clinical Director at the Francis Crick Institute and Chief Investigator for the TRACERx project, emphasized the transformative potential of linking two clonal proliferations—CHIP and solid tumor evolution. “This is a first-of-its-kind demonstration at scale that integrates age-related mosaicism in the hematopoietic system with cancer development. As we decode the mutations emerging during aging in bone marrow cells and their systemic effects, we open a new frontier in cancer prevention and treatment.”

Supported by Cancer Research UK and the National Institute of Health and Care Research UCLH Biomedical Research Centre, this landmark study published in the New England Journal of Medicine on April 23, 2025, charts unexplored territory in the intertwined pathologies of aging and cancer. It calls for the oncology community to incorporate the dynamics of clonal hematopoiesis into future clinical trials, risk assessment models, and therapeutic design, heralding a new era of precision medicine informed by the biology of aging.

Subject of Research: Animals
Article Title: Tumor-Infiltrating Clonal Hematopoiesis
News Publication Date: 23-Apr-2025
References: Pich, O. et al. (2025). Tumor-Infiltrating Clonal Hematopoiesis. New England Journal of Medicine.
Keywords: Lung cancer, Myeloid cells

Understanding the immune landscape of endometrial carcinoma is pivotal. In the exploration of EC, researchers have identified several key immune cell populations that significantly influence tumor dynamics. Among these are T cells, which are integral to anti-tumor immunity; B cells, which produce antibodies; macrophages, known for their versatility in phagocytosis and cytokine production; natural killer cells, which target and lyse tumor cells; and dendritic cells, which serve as crucial antigen-presenting cells. Each of these immune cells plays a distinct role, operating within a highly regulated network that can either hinder or promote tumor growth.

This review emphasizes the concept of immune checkpoint pathways, particularly the PD-1/PD-L1 axis, which has gained attention for its role in immune evasion. Tumors like endometrial carcinoma have adeptly learned to exploit these pathways to dampen immune responses, creating a microenvironment that protects cancer cells from being targeted by the body’s natural defense mechanisms. Researchers are now delving deeper into the nuances of these pathways, examining how their manipulation could potentially reverse immune suppression and bolster anti-tumor activity.

In addition to immune checkpoints, the review scrutinizes the roles of cytokines and chemokines in shaping the immune response in endometrial carcinoma. These signaling molecules are vital for coordinating the movement and functioning of immune cells within the tumor’s milieu. Specific chemokines can either recruit immune cells to the tumor site or promote an anti-inflammatory environment that favors tumor growth. Understanding this delicate balance can illuminate new strategies for immunotherapeutic approaches that could potentially turn the tide in favor of more successful treatment outcomes.

A critical factor discussed is the polarization of macrophages, which can adopt pro-tumor or anti-tumor functions depending on the signals they receive from their environment. For instance, tumor-associated macrophages often exhibit immunosuppressive qualities that facilitate cancer progression and metastasis. By understanding the factors that dictate this polarization, researchers can develop targeted therapies aimed at converting pro-tumor macrophages into their anti-tumor counterparts, thus enhancing the immune response against endometrial carcinoma.

Furthermore, the review emphasizes the importance of understanding auxiliary immune cells, such as regulatory T cells (Tregs), which play key roles in maintaining immune homeostasis. However, in the case of tumors like EC, Tregs are often markers of an immunosuppressive landscape. By dissecting their mechanisms of action, researchers hope to discover how best to overcome the immune suppression they engender, possibly through combination therapies that could enhance the efficacy of existing immunotherapies.

The clinical implications of these findings cannot be overstated. The review posits that tailored immunotherapies, designed based on specific immune responses within an individual patient’s tumor microenvironment, could lead to improved outcomes. This highlights a significant pivot toward personalized medicine in oncology, where therapies are not merely one-size-fits-all but rather intricately aligned to each patient’s unique cancer biology.

There is also a call for further exploration into potential biomarkers for predicting responses to immunotherapy. Identifying such biomarkers could be a game-changer, enabling researchers and clinicians to select appropriate treatments for patients based on their individual biologic responses. This, in turn, may lead to more successful therapeutic strategies and enhanced survival rates for those affected by endometrial carcinoma.

The message distilled from this review is clear: the interplay of immune cells within the endometrial cancer microenvironment is complex and vital to understand. As researchers continue to explore these interactions, the potential for novel treatment strategies becomes increasingly evident. The hope is that insights garnered will pave the way for innovative therapies, while also inspiring further studies aimed at deciphering the underlying mechanisms at play.

Such comprehensive analyses are instrumental in transforming our approach to cancer research. The exploration of immune-tumor interactions underscores the urgent need for continued investment in foundational research and clinical trials aimed at harnessing the immune system as a powerful ally in the fight against cancer. As this body of work evolves, it lays a promising foundation for future breakthroughs, ensuring that targeted therapies remain at the forefront of endometrial cancer management.

The potential for innovation is vast, and as scientists delve deeper into the nuances of immune regulation in endometrial carcinoma, we may soon see clinical applications that enhance patient quality of life and survival. With every new discovery, we move closer to a future where cancer is managed with the precision and efficacy it demands, empowering researchers and clinicians alike in their relentless pursuit of better outcomes for all cancer patients.

In summary, the findings from the review not only contribute to our understanding of endometrial carcinoma but also offer a compelling vision for the future of cancer treatment, where insights from immune research translate into tangible benefits in patient care. The path forward will require collaboration, ingenuity, and a steadfast commitment to unraveling the mysteries of the immune system in its battle against cancer.

Subject of Research: Tumor-infiltrating immune cells and their role in endometrial carcinoma
Article Title: Molecular mechanism of tumor-infiltrating immune cells regulating endometrial carcinoma
News Publication Date: 2025
Web References: Not provided
References: Not provided
Image Credits: Genes & Diseases (Credit)

Keywords: endometrial carcinoma, immune microenvironment, immunotherapy, cytokines, chemokines, personalized medicine, tumor progression, immune evasion, T cells, regulatory T cells, macrophages, biomarkers

The study meticulously delineates the immune architecture present in pancreatic ductal adenocarcinoma (PDAC), highlighting its unique properties compared to other cancer types. By constructing an intricate single-cell map of tumor-infiltrating immune cells obtained from twelve patients, the researchers were able to perform comprehensive assessments of both peripheral and intratumoral immune responses. This single-cell multi-omics approach integrates gene expression profiling with single-cell T cell receptor and B cell receptor sequencing, enabling a detailed analysis of protein expression patterns on immune cells. The insights gained from this extensive mapping are critical for understanding how pancreatic tumors evade the immune system’s defenses.

In essence, the research indicates that pancreatic tumors are not uniformly immunogenic; rather, immune cell infiltration varies significantly among different tumor microenvironments. Some tumors appear more amenable to T cell infiltration, while others are predominantly infiltrated by myeloid cells such as macrophages, which can exhibit both pro-inflammatory and immunosuppressive functions. This differentiation in immune cell populations highlights the necessity for tailored immunotherapies that can leverage these diverse immune landscapes effectively.

The lead author, Dr. Shivan Sivakumar, emphasizes the urgency of this research, noting the limited effectiveness of current immunotherapies, particularly checkpoint inhibitors, in managing pancreatic cancer. The team’s findings suggest a paradigm shift towards adopting macrophage-targeted strategies, especially in tumors characterized by dense myeloid cell infiltration. This approach amplifies the importance of developing therapies that not only engage T cells but also modify the activity of macrophages and other myeloid lineage cells that could play critical roles in either promoting or inhibiting anti-tumor responses.

In uncovering the distinct immune environments within pancreatic cancer, the research team also highlights the potential therapeutic value embedded in targeting specific immune cell types. Activated regulatory T cells (Tregs) and B cells have been identified as key players in modulating immune responses to tumors. This insight is pivotal as it provides a clear framework for stratifying patients who might benefit from specific immunotherapies aimed at either enhancing immune activity or countering suppression within the tumor microenvironment.

Notably, the study underscores the therapeutic potential of targeting molecules like TIGIT and CD47, which have emerged as promising candidates in pancreatic cancer treatment. These targetable pathways could redefine the standard of care through the development of novel agents aimed at restoring immune function within the tumor. As the research advances, there is growing anticipation around the possibilities of combining various strategies, such as augmenting B cell responses and depleting suppressive macrophages, to optimize treatment outcomes.

Dr. Rachael Bashford-Rogers, a senior author of the study, reinforces the significance of these findings by articulating the need for further investigation into the evolving dynamics of immune infiltration within pancreatic tumors over time. The ability to monitor how immune cell populations change in response to therapies holds transformative potential for the development of individualized treatment protocols that can more effectively manage this formidable disease.

Given the stark realities surrounding pancreatic cancer, with significantly low survival rates and often late-stage diagnoses, the implications of this research are both timely and critical. Patients diagnosed with pancreatic cancer frequently confront grim prognoses, with less than 7% achieving a five-year survival rate. The identification of innovative therapeutic strategies rooted in a deeper understanding of the tumor-immune interaction landscape becomes an essential component of extending survival and improving quality of life for patients.

The study does not merely present data but also advocates for a reevaluation of existing therapeutic paradigms in treating pancreatic cancer. As noted by Dr. Sivakumar, the urgency derived from the high recurrence rates following surgery, which exceed 80%, underscores the importance of ongoing research and clinical trials. Initiatives like the mRNA vaccine study represent a proactive step towards integrating cutting-edge technology with traditional treatment modalities to prevent recurrence and enhance long-term outcomes.

Moreover, this meticulous investigation paves the way for the future design of more effective immunotherapy trials, which could ultimately lead to significant breakthroughs in the treatment landscape. By fostering collaborations between academia and the private sector, new avenues of drug development can emerge, translating research findings into actionable therapeutic options for patients afflicted with pancreatic cancer.

In conclusion, the research emanating from the collaborative efforts of the University of Birmingham and University of Oxford forms a solid foundation for future inquiries into the immune dynamics of pancreatic cancer. With a concerted focus on understanding the intricacies of immune infiltration and its impact on treatment response, there lies a prudent opportunity to revamp the therapeutic landscape for this challenging malignancy. As further studies materialize based on these promising findings, there is cautious optimism that the tide may be turning in the battle against pancreatic cancer, potentially translating into improved prognoses for those impacted by this devastating disease.

Subject of Research:
Article Title: Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms
News Publication Date: 6-Feb-2025
Web References: Nature Communications
References: DOI: 10.1038/s41467-024-55424-2
Image Credits:

Keywords

Pancreatic cancer, Immune mapping, Precision therapy, Immunotherapy, Macrophages, T cells, Myeloid cells, Cancer research, Tumor microenvironment, Cancer survival rates, Immune therapeutics.